Back to results
US 2021/0171977 A1Published application
Synthetic promoters
AssigneeMassachusetts Institute of Technology
InventorsTimothy Kuan-Ta Lu, Lior Nissim, Ming-Ru Wu
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure provide synthetic promoters that are differentially modulated between certain diseased cells (e.g., cancer cells) and normal cells (e.g., non-cancer cells). These synthetic promoters are useful, for example, for targeted expression of therapeutic molecules in diseased cells.
Claims15
An engineered nucleic acid comprising a promoter that comprises the following consensus sequence:
- TFBS-AGA-TFBS- TCG-TFBS-GAC-TFBS-CTA-TFBS-ACT-TFBS-TGC-TFBS-GTA-TFBS, wherein TFBS is a transcription factor binding site sequence of Table 5.
An engineered nucleic acid comprising a promoter that comprises a nucleotide sequence identified by any one of SEQ ID NOS:
- 1-12263, or a nucleotide sequence at least 95% identical to a nucleotide sequence identified by any one of SEQ ID NOS:
- 1-12263.
Dependencies are inferred from the claim text.